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Background  and  purpose:  Folate  and  vitamin  B12  are  essential  components  in  the metabolism  of  homocys-
teine  (Hcy).  Hyperhomocysteinemia  has  been  implicated  in endothelial  dysfunction  and  cardiovascular
disease.  However,  the  association  of Hcy,  vitamin  B12,  and  folic  acid with  cardiovascular  risk factors  in
patients with  coronary  artery  disease  (CAD)  has  not  been  studied  in Indian  patients.  This  study  was
conducted  with  the aim to  evaluate  the  relationship  of  vitamin  B12,  folic  acid,  and  Hcy  levels  with
cardiovascular  risk  factors  in  subjects  with  known  CAD.
Methods  and  subjects:  Three  hundred  patients  (216 men;  84  women;  aged  25–92 years)  who  had  CAD
on  angiography  were  included  in this  study  consecutively.  All  patients  were  evaluated  for  anthropom-
etry  and  cardiovascular  risk  factors,  and  blood  samples  were  collected  for  biochemical,  nutritional,  and
inﬂammatory  markers.
Results:  Percentage  of vitamin  B12  and folate  deﬁciency  was  86.7%  and 2.7%, respectively.  Hyperhomo-
cysteinemia  was  present  in 95.3%  patients.  Vitamin  B12  levels  were  signiﬁcantly  lower  and  Hcy levels
were  signiﬁcantly  higher  in  subjects  with  dyslipidemia,  DM,  and/or  hypertension.  Serum  vitamin  B12
was inversely  associated  with  triglyceride  and  very  low-density  lipoprotein  (VLDL)  and  positively  with
high-density  lipoprotein  (HDL).  Hcy  was  positively  associated  with  triglyceride  and  VLDL  and  negatively
with  HDL.  Vitamin  B12  was  inversely  correlated  with  inﬂammatory  markers  (high-sensitivity  C-reactive
protein  and  interleukin-6)  directly  related  to insulin  resistance  whereas  Hcy  showed  the opposite  pattern.
Conclusions:  Serum  vitamin  B12  deﬁciency  and  hyperhomocysteinemia  are  related  with  cardiovascular
risk  factors  in Indian  patients  with  CAD.
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Homocysteine (Hcy) is a sulfhydryl containing amino acid pro-
uced by demethylation of an essential amino acid (methionine).
ethylation of Hcy, catalyzed by methionine synthetase produces
ethionine [1].  Folate and vitamin B12 are essential components
n the metabolism of Hcy, which occurs through remethyla-
ion to methionine or trans-sulfuration to cysteine. The enzyme
ethylene-tetrahydro-folate-reductase (MTHFR) is responsible forhe reduction of 5,10-methylene-THF to 5-methyl-THF, where
itamin B12 acts as a cofactor [2].  Hcy-mediated enhanced lipid
eroxidation and generation of free radicals results in inﬂammation
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and acute endothelial dysfunction, which accelerates atheroscle-
rotic process predisposing to cardiovascular disease. The ﬁrst
clinical study by Wilcken and Wilcken in 1976, supported the the-
ory that coronary artery disease (CAD) is associated with higher
levels of Hcy [3].  It has also been demonstrated that in the presence
of traditional risk factors, Hcy plays a permissive role in endothelial
damage. Low vitamin B12 concentration and hyperhomocysteine-
mia  are common in Indian men, particularly in vegetarians and
urban residents [4].
Many studies have been undertaken to examine the relation
between plasma Hcy and coronary heart disease [5,6]. The gen-
eral outcome supports the hypothesis that an elevated plasma Hcy
concentration leads to an increased risk of cardiovascular disease.
However, there are few studies that showed the association of
Hcy, vitamin B12, and folic acid with cardiovascular risk factors
in patients with known CAD. This study was  conducted with the
aim to evaluate the relationship of vitamin B12, folic acid, and Hcy
levels with cardiovascular risk factors in subjects with known CAD.
vier Ltd. All rights reserved.
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aterials and methods
Patients reporting with chest pain were evaluated by a car-
iologist and underwent coronary angiography based on clinical
nd investigational data. Blood samples were collected and if CAD
as detected on angiography, patients were included in the study.
atients with chronic kidney disease, hepatic dysfunction, known
ndocrinal (except diabetes mellitus) or rheumatologic diseases or
hronic infections, and patients being treated with vitamins were
xcluded from the study. All cases were interviewed using a ques-
ionnaire, which included data on smoking and physical activity.
Height, weight, waist and hip circumference were measured.
ody mass index (BMI) was calculated by dividing weight in kilo-
rams with square of height in meters. Waist hip ratio (WHR) is
aist circumference divided by hip circumference. Data on clinical
istory of hypertension (HTN) and diabetes mellitus (DM) and med-
cations (antihypertensive, lipid lowering, and oral hypoglycemic
gents) were also acquired. Conventional risk factors were deﬁned
s follows: BMI  < 25 normal, ≥25 overweight/obese, DM (by history
nd treatment), and HTN (systolic and diastolic blood pressures
bove 140 and 90 mmHg, respectively).
Fasting blood samples were collected after 14 h of fasting. Lipids
ere measured by using CHOD PAP, LIP/GK, enzymatic reaction
espectively and low-density lipoprotein cholesterol (LDL-C) and
ery low density lipoprotein cholesterol (VLDL-C) were calculated
y Freidewald formula. Inter assay 3.84% and intra precision was  2%,
espectively for all biochemical parameters. Hemoglobin (Hb)A1C
as measured by boronate afﬁnity assay. Tumor necrosis factor-
lpha (TNF-),  interleukin-6 (IL6), highly sensitive C-reactive
rotein (hsCRP), and Hcy were measured by enzyme linked
mmunosorbent assay method with kits manufactured by Gen-
robe Diaclone, Besanc¸ on, France, Biocheck, Foster City, CA, USA,
nd Axis-shield Diagnostic Ltd., Dundee, UK respectively. Insulin,
itamin B12, and folic acid were measured by Microparticle enzyme
mmunoassay (MEIA), and Ion Capture MEIA method respectively
ith commercial kits supplied by Abbott Laboratory, Abbott Park,
L, USA. Intra assay and inter assay precision were <5% and <10%,
espectively for above parameters. Insulin resistance and sensitiv-
ty was calculated by using homeostatic model analysis (HOMA)
able 1
asic characteristics of the study population.
Parameters Male (n = 216)
Mean ± SD
Age (years) 60.8 ± 12.3 
BMI  (kg/m2) 27.65 ± 3.69 
WHR  0.92 ± 0.05 
DM,  n (%) 86(68.8%) 
HTN,  n (%) 72 (75.8%) 
DM  & HTN, n (%) 59 (63.4%) 
Smoking, n (%) 82 (73.9%) 
Dyslipidemia, n (%) 81 (65.3%) 
Cholesterol, mmol/l (mg/dl) 4.5 ± 1.1 (177.7 ± 44.4) 
Triglyceride, mmol/l (mg/dl) 2.24 ± 0.51 (198.8 ± 45.4) 
HDL,  mmol/l (mg/dl) 1.0 ± 0.23 (39.3 ± 9.2) 
LDL,  mmol/L (mg/dl) 2.7 ± 1.27 (104.4 ± 49.2) 
VLDL, mmol/L (mg/dl) 0.86 ± 0.24 (33.4 ± 9.6) 
Insulin, pmol/l (mU/L) 342.3 ± 288.2 (49.3 ± 41.5) 
HOMA IR 16.6 ± 17.01 
QUICKI 0.28 ± 0.039 
IL-6  (pg/ml) 62.3 ± 73.8 
TNF-  (pg/ml) 22.8 ± 42.2 
hsCRP (mg/L) 11.9 ± 10.03 
Vitamin B12, pmol/L (pg/ml) 167.4 ± 297.7 (226.9 ± 403.5) 
Homocysteine, mol/L (mg/L) 36.5 ± 13.58 (4.93 ± 1.83) 
Folic  acid, nmol/L (ng/ml) 18.1 ± 16 (8.0 ± 7.1) 
MI, body mass index; WHR, waist hip ratio; DM,  diabetes mellitus; HTN, hypertension; H
LDL,  very low density lipoprotein cholesterol; HOMA IR, homeostatic model analysis calc
nterleukin-6; TNF-, tumor necrosis factor-alpha; hsCRP, highly sensitive C-reactive proiology 61 (2013) 289–294
[HOMA-insulin resistance = fasting insulin (IU/ml) × fasting glu-
cose (mmol/l)/22.5 and quantitative insulin sensitivity check index
(QUICKI)] [QUICKI = 1/log(fasting insulin U/mL) + log(fasting glu-
cose mg/dL)] respectively. Atherogenic dyslipidemia was deﬁned
as triglyceride level ≥ 1.69 mmol/L (≥150 mg/dl), and high-density
lipoprotein cholesterol (HDL) cholesterol level < 1.03 mmol/L
(<40 mg/dl). Vitamin B12 deﬁciency was deﬁned by <147.6 pmol/L
(<200 pg/ml), folate deﬁciency by <3 ng/ml, and hyperhomocys-
teinemia by >15 mol/L (>2.02 mg/L). For comparison we have
divided all subjects into three groups according to vitamin B12
levels: <73.8 pmol/L (<100 pg/ml) – group1; 73.8–147.6 pmol/L
(100–200 pg/ml) – group 2; >147.6 pmol/L (>200 pg/ml) – group 3;
and two groups according to Hcy levels: ≤15 mol/l (≤2.02 mg/L)
– group 1; >15 mol/l (>2.02 mg/L) – group 2.
Informed written consent was obtained from all patients and the
study protocol was  approved by the institutional ethics and review
committee.
Statistical analysis was carried out using EPI Info, version 3.5.3
(CDC; Atlanta, GA, USA) and SPSS Version 20 (Chicago, IL, USA).
Data are presented as mean ± SD, median (range) or number (%)
unless speciﬁed. All parametric data were analyzed by Student’s t-
test. If Bartlett’s chi-square test for equality of population variances
was <0.05 then Kruskal–Wallis test was applied. Pearson correla-
tion was  used to evaluate the correlation between inﬂammatory
markers, insulin resistance, and nutritional factors. Multiple regres-
sion analysis was  performed after adjustment for age, sex, BMI,
and presence of HTN. All non parametric data were analyzed by
chi-square test. A p-value of <0.05 was  considered statistically sig-
niﬁcant.
Results
Three hundred patients with known cardiovascular disease (216
men; 84 women; aged 25–92 years) were studied. The percentages
with vitamin B12 and folate deﬁciency were 86.7% and 2.7%, respec-
tively. Subjects with hyperhomocysteinemia were 95.3%. Table 1
shows the baseline characteristics of the subjects studied. There
was no gender difference in vitamin B12 and folic acid (Table 1).
Female (n = 84)
Mean ± SD
p-Value
61.03 ± 12.9 0.9205
28.5 ± 4.07 0.0762
0.91 ± 0.06 0.1185
39 (31.2%) 0.3613
23 (24.2%) 0.3914
34 (36.6%) 0.038
29 (26.1%) 0.6738
43 (34.7%) 0.0422
4.6 ± 1.2 (181.2 ± 48.8) 0.5505
1.97 ± 0.54 (174.5 ± 48.3) 0.428
0.9 ± 0.23 (38 ± 9.2) 0.2528
2.8 ± 1.39 (108.3 ± 53.8) 0.5468
0.88 ± 0.27 (34.1 ± 10.7) 0.6378
362.5 ± 334.7 (52.2 ± 48.2) 0.6018
22.2 ± 28.6 0.5029
0.27 ± 0.047 0.4649
70.1 ± 78.9 0.422
28 ± 38.7 0.3373
11.1 ± 8.72 0.556
99.7 ± 64.5 (135.2 ± 87.5) 0.0738
35.0 ± 18.77 (4.73 ± 2.53) 0.0269
17.6 ± 15.1 (7.8 ± 6.7) 0.7980
DL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol;
ulated insulin resistance; QUICKI, quantitative insulin sensitivity check index; IL-6,
tein.
f Card
m
i
r
i
n
a
f
b
a
a
a
t
(
T
V
D
T
C
H
pN. Mahalle et al. / Journal o
Subjects with DM and/or HTN had signiﬁcantly lower vita-
in  B12 levels (Table 2). Serum vitamin B12 concentration was
nversely related with inﬂammatory markers and was  positively
elated to insulin sensitivity (Table 3). Vitamin B12 levels were low
n subjects with dyslipidemia (Table 2). Serum vitamin B12 was
egatively correlated with dyslipidemia (Table 3) and this associ-
tion remained unchanged even after adjustment for all other risk
actors: age, sex, BMI, WHR, physical inactivity, smoking, and dia-
etes (Supplementary Table 1). Serum vitamin B12 was  inversely
ssociated with triglycerides and VLDL, and positively with HDL
fter adjustment with other risk factors. However, there was no
ssociation of vitamin B12 with total cholesterol and LDL choles-
erol (Table 4).
Subjects with DM and/or HTN had signiﬁcantly higher Hcy levels
Table 2). Subjects with dyslipidemia had signiﬁcantly higher Hcy
able 2
itamin B12, homocysteine, and folic acid levels according to cardiovascular risk factors.
Vitamin B12
pmol/L (pg/ml)
Ho
m
Mean ± SD p-Value Me
DM
Yes 131.5 ± 222.2 (178.2 ± 301.2)
0.0014
39
No  160.2 ± 278.5 (217.2 ± 377.4) 33
Smoking
Yes  148 ± 245.3 (200.6 ± 332.4)
0.9893
36
No  148.4 ± 263.6 (201.2 ± 357.3) 36
HTN
Yes 139.9 ±  259.7 (189.6 ± 352.0)
0.4639
38
No  162.4 ± 152.6 (220.1 ± 341.0) 32
DM  & HTN
Yes 119.3 ± 202.5 (161.7 ± 274.5)
0.0002
40
No  161.5 ± 276.9 (218.9 ± 375.3) 34
Dyslipidemia
Yes  64.8 ± 6.2 (87.9 ± 8.5)
<0.0001
50
No 207 ± 322.5 (280.6 ± 437.1) 26
Physical inactivity
Yes 129 ± 177.3 (174.9 ± 240.3)
0.5423
36
No  160.4 ± 295.7 (217.4 ± 400.7) 36
BMI
Normal  < 25 126.7 ± 142.3 (171.8 ± 192.9)
0.4456
36
Overweight/obese ≥ 25 154.2 ± 280 (209.0 ± 379.5) 35
WHR
≤0.9  178.2 ± 323.4 (241.5 ± 438.3)
0.5249
36
>0.9 135.4 ± 221.5 (183.6 ± 300.2) 36
M,  diabetes mellitus; HTN, hypertension; BMI, body mass index; WHR, waist hip ratio.
able 3
orrelation of vitamin B12, homocysteine, and folic acid with cardiovascular risk factors.
Vitamin B12 Ho
r-Value p-Value r-V
Insulin −0.102 0.077 0
HOMA IR −0.124 0.032 0
QUICKI 0.105 0.070 −0
IL-6  −0.091 0.116 0
hsCRP −0.102 0.078 0
TNF  alpha −0.016 0.784 0
DM −0.055  0.339 0
Smoking −0.001 0.989 −0
HTN  −0.042 0.464 0
DM  & HTN −0.076 0.190 0
Dyslipidemia −0.273 <0.0001 0
Physical inactivity −0.060 0.302 0
BMI 0.028 0.634 −0
WHR  −0.026 0.659 −0
OMA IR, homeostatic model analysis calculated insulin resistance; QUICKI, quantitative i
rotein; TNF, tumor necrosis factor; DM,  diabetes mellitus; HTN, hypertension; BMI, bodiology 61 (2013) 289–294 291
levels. Hcy was positively correlated with dyslipidemia (Table 2)
which persisted in stepwise multiple regression analysis even
after adjustment with other risk factors: sex, BMI, WHR, phys-
ical inactivity, smoking, and diabetes (Supplementary Table 2).
Hcy was positively correlated with insulin, insulin resistance, IL-
6, and hsCRP (Table 3 and Fig. 1). Hcy was positively associated
with triglyceride and VLDL, and negatively with HDL after adjust-
ment with all risk factors (Table 4 and Fig. 1). However, there was
no association of Hcy with total cholesterol and LDL cholesterol
(Table 4).
All subjects were grouped according to vitamin B12 levels and
Hcy levels. Insulin levels and HOMA-IR decreased from group
1 to group 3; whereas insulin secretion assessed by QUICKI
improved. Similarly inﬂammatory markers (hsCRP, IL-6, and
TNF-) also decreased from group 1 to group 3. Subjects with
mocysteine\
ol/L (mg/L)
Folic acid
nmol/L (ng/ml)
an ± SD p-Value Mean ± SD p-Value
.2 ± 15.9 (5.29 ± 2.14)
0.0026
17.4 ± 14.2 (7.7 ± 6.3)
0.5116.9 ± 14.2 (4.58 ± 1.91) 18.5 ± 16.7 (8.2 ± 7.4)
.0 ± 13.2 (4.86 ± 1.78)
0.5104
17.9 ± 15.4 (7.9 ± 6.8)
0.9517.1 ± 16.2 (4.88 ± 2.19) 18.1 ± 16 (8.0 ± 7.1)
.1 ± 15.8 (5.15 ± 2.13)
0.0036
16.9 ± 14.5 (7.5 ± 6.4)
0.2252.8 ± 13.5 (4.43 ± 1.82) 19.9 ± 17.9 (8.8 ± 7.9)
.3 ± 16.0 (5.44 ± 2.16)
0.0011
16.9 ± 13.5 (7.5 ± 6.0)
0.4439.2 ± 14.4 (4.62 ± 1.94) 18.5 ± 16.7 (8.2 ± 7.4)
.0 ± 12.4 (6.75 ± 1.67)
<0.0001
19.7 ± 16.9 (8.7 ± 7.5)
0.1381.3 ± 7.2 (3.55 ± 0.97) 16.9 ± 14.7 (7.5 ± 6.5)
.2 ± 15.7 (4.89 ± 2.12)
0.9267
16.3 ± 14 (7.2 ± 6.2)
0.1617.1 ± 14.9 (4.88 ± 2.01) 19 ± 16.7 (8.4 ± 7.4)
.8 ± 17.9 (4.97 ± 2.41)
0.8742
18.8 ± 16.7 (8.3 ± 7.4)
0.6713.9 ± 14.3 (4.85 ± 1.93) 17.9 ± 15.6 (7.9 ± 6.9)
.2 ± 15.4 (4.89 ± 2.08)
0.9317
17.6 ± 15.1 (7.8 ± 6.7)
0.8032.0 ± 15.1 (4.86 ± 2.04) 18.1 ± 16 (8.0 ± 7.1)
mocysteine Folic acid
alue p-Value r-Value p-Value
.313 <0.0001 −0.058 0.315
.377 <0.0001 −0.017 0.775
.365 <0.0001 −0.093 0.106
.296 <0.0001 0.050 0.387
.313 <0.0001 0.023 0.685
.099 0.088 −0.028 0.627
.173 0.003 −0.027 0.636
.003 0.965 −0.019 0.741
.168 0.004 −0.092 0.111
.187 0.001 −0.042 0.471
.770 <0.0001 0.068 0.241
.007 0.898 −0.041 0.482
.041 0.474 0.043 0.459
.022 0.704 −0.001 0.987
nsulin sensitivity check index; IL-6, interleukin 6; hsCRP, highly sensitive C-reactive
y mass index; WHR, waist hip ratio.
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yperhomocysteinemia were more insulin resistant (HOMA-IR)
nd had decreased beta cell function (QUICKI). hsCRP levels were
igniﬁcantly higher in subjects with hyperhomocysteinemia (Sup-
lementary Table 3). There was no correlation between body mass
ndex, WHR, and physical activity with folic acid. Folic acid levels
id not differ and show any relation with any risk factors. Folic acid
evels were comparable in subjects with and without dyslipidemia.
iscussion
Increased plasma Hcy levels are positively associated with new
nset CAD, recurrent cardiovascular events, extent of myocardial
amage, and mortality in patients with ischemic heart disease
7,8]. Elevated homocysteine levels are also related to intima media
hickness [9] and to severity of CAD in Japanese patients [10], but
ere unrelated to major cardiovascular adverse events in patients
ith CAD who had undergone percutaneous coronary intervention
11]. However, few studies with small numbers of subjects were
able 4
ssociation of vitamin B12 and homocysteine with lipids.
Univariate analysis
with vitamin B12
Multiple regression with
vitamin B12 (adjusted with all
other risk factors)
r-Value p-Value Beta coefﬁcient p-Va
Cholesterol −0.010 0.855 −0.032 0.942
Triglyceride −0.140  0.015 −0.965 0.031
HDL  0.136 0.019 5.017 0.030
LDL  −0.009 0.882 −0.022 0.957
VLDL  −5.271 0.015 −4.825 0.031
DL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipo
ig. 1. Scatter plot with trendline showing relationship of homocysteine with HOMA-IR, h
nsulin resistance; hsCRP, highly sensitive C-reactive protein; HDL, high-density lipoprotiology 61 (2013) 289–294
able to demonstrate this relation [1,12].  It has been postulated
that higher Hcy levels lead to epigenetic modiﬁcation by macro-
molecular global DNA methylation, which is associated with CAD
in Indian patients [13]. We  evaluated the association of Hcy lev-
els and related nutritional markers (vitamin B12, folic acid) with
known cardiovascular risk factors in 300 subjects with CAD. Most
of the patients were vitamin B12 deﬁcient (86.7%) but a few were
folate deﬁcient (2.7%). Another study from India also reported high
prevalence (87%) of vitamin B12 deﬁciency Vitamin B12 deﬁciency
varied from 1.5% to 26.6% in other countries [2,14–16]. The differ-
ences in prevalence of serum vitamin B12 deﬁciency and folate can
be explained on the basis of the different cutoff points deﬁned for
vitamin B12 deﬁciency and dietary intake of vitamin B12 according
to dietary differences [17]. Hyperhomocysteinemia was  present in
95.3% patients in the present study. High prevalence of hyperho-
mocysteinema was also reported from the same region of India in
one study (79% in urban population) [18] and from northern part
of India (84%) [17]. A lower prevalence of hyperhomocysteinemia
Univariate analysis
with homocysteine
Multiple regression with
homocysteine (after adjustment
with all other risk factors)
lue r-Value p-Value Beta coefﬁcient p-Value
0 −0.026 0.651 −0.012 0.5306
 0.434 <0.0001 0.133 <0.0001
 −0.442 <0.0001 −0.707 <0.0001
0 −0.023 0.696 −0.010 0.5621
 0.434 <0.0001 0.665 <0.0001
protein.
sCRP, triglycerides, and HDL levels. HOMA IR, homeostatic model analysis calculated
ein cholesterol.
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6.1–47.4%) was reported from other countries [2,11,19,20]. More-
ver, mean Hcy levels show a geographical pattern with lower
evels reported from European countries [5–9], which increases on
oving to Asian countries [1,2,16,17]. It has been suggested that
nadequate plasma concentration of vitamin B12 is a contributing
actor in approximately 2/3 of all cases of hyperhomocysteinemia
19] and low vitamin B12 concentration contributed 28% to the
isk of hyperhomocysteinemia [4].  In this study we  have observed
igher mean Hcy levels because we have selected patients who
lready had CAD. The association of hyperhomocysteinemia with
AD seems stronger in Indian patients. In a case–control study in
ndian subjects with or without CAD, age adjusted odds ratio for
omocysteine (10.54, 95%CI 3.11–35.78) was second to smoking
mong various cardiovascular risk factors [21]. Hyperhomocys-
einemia has been reported in Indian children and adolescents and
ound to be related to atherogenic dyslipidemia [22]. Higher levels
f homocysteine have been observed in Indian subjects compared
o migrant Indians [23]. Hence, homocysteine levels are an impor-
ant determinant of cardiovascular risk factors in Indian subjects
ith or without CAD.
Serum vitamin B12 was higher in males as compared to females
ut was statistically comparable. A study from Korea among
iddle-income groups reported signiﬁcantly lower levels in males
han females [11]. Hcy levels were not correlated with age in the
resent study, but other studies have shown a positive correlation
11,19,20]. Hcy levels were higher in males compared to females in
ur study which has been also observed in other studies [7,24].  Sim-
lar to our study no correlation was detected among Hcy and BMI
nd WHR  by others [25,26] whereas one study reported higher BMI
nd WHR  in the group with high Hcy as compared to a group with
ormal Hcy levels [27]. There was no difference in levels of Hcy,
itamin B12, and folate levels between smokers and non-smokers.
thers have reported lower levels of serum folate and higher Hcy
n smokers when compared with non-smokers [28].
In the present study, vitamin B12 was lower in patients with
M and dyslipidemia but was independently associated with dys-
ipidemia only. Similar to our study, low serum levels of vitamin
12 were observed in Omani adults with DM [29]. Hcy was higher
n DM and/or HTN subjects in the present study. Others have also
bserved higher Hcy levels in patients with DM [25,30].  One study
eported higher blood pressure in high Hcy group as compared to
he group with normal Hcy level [25].
Hcy levels were higher in subjects with lipid abnormalities
han without them in our study. An association between hyper-
ipidemia and hyperhomocysteinemia has been reported by Obeid
t al. [31]. Higher plasma Hcy was associated with lower HDL lev-
ls and higher triglyceride levels in our study. A similar association
as been reported in Indian adolescents [22]. Hcy was unrelated
o serum triglyceride and HDL cholesterol levels in one study
25]. Hcy accumulation leads to the synthesis and accumulation of
-adenosyl-l-homocysteine, which is an inhibitor of S-adenosyl-
-methionine-dependent methyltransferases and responsible for
ethylation of nucleic acids, proteins, and lipids. This will cause
ypomethylation of various enzymes and accumulation of lipids in
iver along with increased levels of triacyglycerols [32]. Decreased
ethyl group will decrease the synthesis of phosphatidylcholine,
ajor phospholipids required for VLDL assembly and homeostasis
31].
Vitamin B12 levels were negatively correlated with HOMA-IR
nd insulin levels in the present study. A similar association has
een observed in women with polycystic ovary syndrome [33].
ontrary to this, a cross-sectional study conducted in 135 Asian
ndian women found no correlation between serum vitamin B12
nd HOMA IR [16]. Vitamin B12 treatment improved insulin
esistance and endothelial dysfunction, along with decreasing
cy levels, in patients with metabolic syndrome, suggesting thatiology 61 (2013) 289–294 293
vitamin B12 has several beneﬁcial effects on cardiovascular disease
risk factors. However, a systematic review of cohort studies showed
limited evidence of vitamin B12 deﬁciency and morbidity and
mortality from cardiovascular disease [34], and a meta-analysis of
several studies done with vitamin B12 and folate supplementation
failed to show a decrease in coronary artery events [35].
In the present study, subjects with hyperhomocysteinemia had
signiﬁcantly high HOMA IR index but insulin levels were compa-
rable. Hcy had a positive association with both insulin and HOMA
IR. The Framingham offspring study demonstrated a modest asso-
ciation between hyperinsulinemia and fasting Hcy levels [36]. In
Japanese diabetic patients, insulin resistance was an independent
predictor of total Hcy levels and insulin and HOMA IR were higher
in high Hcy group in subjects with type 2 DM as compared to a
group with normal Hcy levels [26]. However, other studies failed
to show a correlation between Hcy and insulin sensitivity in male
patients [25] and in healthy pre-menopausal South Asian women
[37].
In our study, Hcy levels were correlated with IL-6 and hsCRP
levels. A large observational study among women (Nurses’ Health
Study) found a positive association between total Hcy and cytokines
IL-6 and CRP along with soluble TNF receptor. A large number
of studies have provided evidence of the role of inﬂammation
in the development and progression of atherosclerotic processes
[16,33]. This may  in part explain the observed association between
high circulating concentrations of Hcy and cardiovascular diseases
described in many observational studies [1–3].
In the present study, Hcy was  inversely associated with plasma
vitamin B12 (r = −0.285, p < 0.001). Hcy exhibited an inverse asso-
ciation with plasma folate (r = −0.3 to −0.37) and vitamin B12
(r = −0.2 to −0.22) in other studies [1,14,19,20]. Contrary to the
most of the studies, we were unable to observe an inverse rela-
tion between serum folate levels. In a prospective study using
Mendelian randomization, it was shown that individuals with
MTHFR 677TT genotype had elevated Hcy with low-normal folate,
whereas those with high-normal folate had normal Hcy concentra-
tions [38]. A similar observation was made by Indian studies [39].
A study in an Indian population revealed a signiﬁcant association
of Hcy levels with MTHFR A1298C polymorphism which was more
common than MTHFR 677TT genotype [40]. However, other stud-
ies were unable to demonstrate a relation between Hcy levels and
MTHFR 677TT polymorphism [41]. This may explain the observed
association of folate with Hcy in western populations. Folate acts
indirectly through vitamin B12 as a methyl donor to Hcy. Hence, a
correlation of serum folate and Hcy is evident in studies in popu-
lations with vitamin B12 sufﬁciency. In our population, there was
high intake of folic acid and low percentage of folic acid deﬁciency
in the presence of high vitamin B12 deﬁciency, which may  have
masked the relation between serum folate and Hcy [39].
There were some limitations to our study. Firstly, we have not
taken a control group. We  wanted to study a population with con-
ﬁrmed CAD because they are more likely to reveal alterations in
inﬂammatory markers, insulin resistance, and dietary factors being
at the extreme end of the disease spectrum. This will help us in
revealing correlations among these factors. Moreover, apparently
healthy asymptomatic controls do not necessarily have absence
of underlying subclinical CAD. Secondly, being a cross-sectional
study, long-term follow-up data were not available. Thirdly, we
have not included dietary data, as they are part of another paper
under review.Conclusion
Vitamin B12 deﬁciency and hyperhomocysteinemia were asso-
ciated with traditional and non-traditional cardiovascular risk
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actors and were independently associated with dyslipidemia even
fter adjustment for all other risk factors in Indian patients with
AD. Thus, vitamin B12 deﬁciency causing hyperhomocysteinemia
ay  be a risk factor for cardiovascular disease and important for
rediction of future cardiovascular disease.
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